LGG-43. CLINICAL EXPERIENCE OF BRAF AND MEK INHIBITOR THERAPY IN PAEDIATRIC GLIOMA

INTRODUCTION: MAPK pathway activation is a druggable target and characteristic of paediatric low-grade(pLGG) and also found in high-grade glioma(pHGG), typically resulting from BRAFV600E/BRAF-fusion/NF1 mutations. METHODS: A retrospective cohort study of 23 patients, who received BRAF inhibitor mono...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: O’Hare, Patricia, Loka, Thalia, D’Arco, Felice, Depani, Sarita, Michalski, Anthony, Slater, Olga, Jorgensen, Mette, Jacques, Thomas, Hargrave, Darren
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2018
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012654/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.384
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi